References
- ParisiRSymmonsDPMGriffithsCEMon behalf of the Identification and Management of Psoriasis and Associated Comor-bidity (IMPACT) project teamGlobal epidemiology of psoriasis: a systematic review of incidence and prevalenceJ Invest Dermatol201313337738523014338
- SaracenoRMannheimerRChimentiSRegional distribution of psoriasis in ItalyJ Eur Acad Dermatol Venereol20082232432918269600
- World Health OrganizationGlobal report on psoriasisWorld Health Organization2016 Available from: http://apps.who.int/iris/bitstream/10665/204417/1/9789241565189_eng.pdfAccessed May 15, 2017
- BrezinskiEADhillonJSArmstrongAWEconomic burden of psoriasis in the United States: a systematic reviewJAMA Dermatol2015151665165825565304
- MenterAGriffithsCEMCurrent and future management of psoriasisThe Lancet20073709583272284
- Humira (adalimumab) prescribing informationEuropean Medicines Agency Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/0081/human_med_000822.jsp&mid=WC0b01ac058001d124Accessed June 28, 2014
- STROBE Statement – Checklist of items that should be included in reports of cohort studies Available from: www.strobe-statement.org/Accessed May 15, 2017
- IolasconGGimiglianoFOrlandoVCapaldoADi SommaCMendittoEOsteoporosis drugs in real-world clinical practice: an analysis of persistenceAging Clin Exp Res2013251S137S14124046038
- CasulaMCatapanoALPiccinelliRAssessment and potential determinants of compliance and persistence to antiosteoporosis therapy in ItalyAm J Manag Care2014205e13814525326928
- OrlandoVGuerrieroFPutignanoDPrescription patterns of antidiabetic treatment in the elderly. Results from Southern ItalyCurr Diabetes Rev201512210010626126718
- World Health OrganizationCollaborating Centre for Drug Statistics Methodology Available from: http://www.whocc.no/atc_ddd_index/Accessed December 19, 2014
- CammarotaSBruzzeseDSarnelliGProton pump inhibitors prescribing following the introduction of generic drugsEur J Clin Invest201242101068107822681176
- CammarotaSBruzzeseDCatapanoALLower incidence of macrovascular complications in patients on insulin glargine versus those on basal human insulins: a population-based cohort study in ItalyNutr Metab Cardiovasc Dis2014241101723806740
- Van de KerkhofPCReichKKavanaughAPhysician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis surveyJ Eur Acad Dermatol Venereol2015292002201025885420
- SpandonaroFAyalaFBerardescaEThe cost effectiveness of biologic therapy for the treatment of chronic plaque psoriasis in real practice settings in ItalyBio Drugs2014283285295
- FeldmanSRZhaoYZhouHHerreraVTianHLiYEconomic impact of above-label dosing with etanercept, adalimumab, or ustekinumab in patients with psoriasisJ Manag Care Spec Pharm201723558358928448778
- IskandarIYKAshcroftDMWarrenRBDemographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions RegisterBr J Dermatol2015173251051825989336
- DoshiJATakeshitaJPintoLBiologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare populationJ Am Acad Dermatol20167461057106526946986
- DETERMINA 9 dicembre 2014 – Regime di rimborsabilità e prezzo del medicinale per uso umano «Remsima» (infliximab), autorizzata con procedura centralizzata europea dalla Commissione Europea. (Determina n. 1471/2014). (14A09840) (GU Serie Generale n. 302 del 31-12-2014). [DETERMINATION 9 December 2014 - Redemption and price regime of the medicinal product for human use “Remsima” (infliximab), authorized with a centralized European procedure by the European Commission. (Determine No. 1471/2014). (14A09840) (GU Series General No. 302 of 31-12-2014)] Available from: http://www.gazzettaufficiale.it/eli/gu/2014/12/31/302/sg/pdfAccessed May 15, 2017 Italian
- PolistenaBCalzavara-PintonPAltomareGThe impact of biologic therapy in chronic plaque psoriasis from a societal perspective: an analysis based on Italian actual clinical practiceJ Eur Acad Dermatol Venereol201529122411241626370321
- FeldmanSRBurudpakdeeCGalaSThe economic burden of psoriasis: a systematic literature reviewExpert Rev Pharmacoecon Outcomes Res20141468570525052261
- FeldmanSRGoffeBRiceGThe challenge of managing psoriasis: unmet medical needs and stakeholder perspectivesAm Health Drug Benefits20169950428465778
- Gazzetta Ufficiale della Repubblica Italiana, Determinazione del 20 marzo 2008. [Official Gazette of the Italian Republic, Determination of the 20th March 2008 Available at http://ww.gazzettaufficiale.it/atto/stampa/serie_generale/originarioAccessed May 15, 2017 Italian